Method of normal microflora composition correction in experiment

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology, and concerns correction of normal microflora composition in experiment. It is ensured by introduction to laboratory animals of 6-piperidinomethyl-2,3-dihydroquercetin- C21H23NO7.

EFFECT: method provides extended range of chemical agents that provide normalisation of colon microflora composition.

1 tbl, 1 ex

 

The invention relates to medicine, namely to experimental pharmacology. The invention is to provide a method of correction of the intestinal microflora using funds derived from a natural flavonoid and have minimal side effects.

It is known used in the experiment and clinical practice drug Intetics that have a positive effect on the normal intestinal microflora [2]. This medicinal product, there are a few unwanted side effects, and today it is obsolete. In addition to this, our offered tool is derived flavonoid - dihydroquercetin produced from natural material [3].

The technical result of the invention consists in the creation of the drug, contributing to the restoration of the composition of the microflora of animals in the experiment and the expansion of the means used for the correction of the normal intestinal flora in laboratory animals in the experiment.

The method of application of the synthesized compound NC-3 (6-piperidinomethyl-2,3-dihydroquercetin, C21H23NO7), which is derived flavonoid dihydroquercetin as a means of positively affecting the composition of the normal microflora of the intestine.

Soy is inania NC-3 synthesized at the Department of organic chemistry, Moscow state pedagogical Institute. Dihydroquercetin, which is the source for obtaining NC-3, has antioxidant properties, but contains a number of impurities, the biological effect which is not taken into account [3]. On this basis, the practical sense is the application of dihydroquercetin derivative, have chemical cleaning and has a number of positive properties.

The method is as follows.

In experiments on outbred mice was studied the effect of NK-3 on correction of the normal intestinal microflora in experimental chemotherapy dysbiosis [1]. Formed dysbacteriosis of the intestine by introducing animals srednestatisticheskiy dose ampioks (4 mg per mouse per day) for 5 days. As a result of this control individuals (as compared with intact) showed a significant increase in the number of enterobacteria (to 10.40,02 CFU/g) and quantitative reduction of the representatives of lactobacilli (to 6.30,4 CFU/g). In the intact group, the quantitative value of enterobacteria was 8.30,07 CFU/g lactobacilli 7,30,3 CFU/g

NC-3 was administered orally at a dose of 100 mg/kg within 7 days after discontinuation of antibiotic 1 hour before feeding animals.

On the 5th day after discontinuation of the antibiotic was determined by the quantitative composition of microflora in the studied animals

Example 1.

Within five steklovarennym mice (21 units) was administered at 4 mg per day of ampioks, what formed their chemotherapeutic dysbacteriosis. On the 6th day from the beginning of the experiment (1st day after discontinuation of the antibiotic) 7 mice daily for 1 hour before feeding received oral Interix at a dose of 100 mg/kg and 7 animals received the same amount of the substance NK-3 (6-piperidinomethyl-2,3-dihydroquercetin, C21H23NO7). The remaining 7 individuals drugs were introduced, this group was the control. On the 7th day after discontinuation of the antibiotic produced quantitative determination of the composition of the microflora (enterobacteria and lactobacilli). The results showed (table 1)that animals receiving NC-3, the most positive changes in the composition of lactobacilli, which was 7.10,7 CFU/G. Therefore, this substance helps to restore the normal microflora of the large intestine in laboratory animals.

Sources of information

1. Kites V.M. study of the influence of enterococci on the normalization of the intestinal microflora in experimental dysbacteriosis/ Vmichael, Tailgater, Snipah etc. // Journal of Microbiology, epidemiology and Immunobiology. - 1989. No. 9.

2. Mashkovsky PPM Medicines. Manual for doctors/ Medmaravis // Ed. 15-E.-Moscow, New wave. 2005

3. E.E. E.YE. TO the question about the identification of flavonoid dihydroquercetin/ Aheneghana, Mporei, He Is Kaziev and other // Journal of General chemistry, 2006. T. Issue 1.

Table 1.
The quantitative composition of lactobacilli and enterobacteria on the seventh day from the beginning of introduction of the investigational drug and the end of the introduction antibiotic
MedicationThe number of bacteria (CFU/g)
LactobacillusEnterobacteria
The intact7,50,38,30,07
Control6,30,410,40,02
Interix6,80,89,10,09
NC-37,20,78,60,01

The correction method of the composition of the intestinal microflora in laboratory animals in experiments involving the introduction of synthetic corrective chemical means, characterized in that such use 6-piperidinomethyl-2,3-dihydroquercetin - C21H23NO7.



 

Same patents:

FIELD: veterinary.

SUBSTANCE: medication includes the following components, wt %: Sulfadimezinum 11.5-15; Trimethoprim 2.0-3.6; Colistin 2.0-3.5; glucose up to 100. Before application the medication is dissolved in warm water or colostrums at 35-37C or fed with forage. The medication is applied daily twice in the dosage of 100 mg/kg of body weight for 3-5 days, or for 5-7 days under severe course of disease.

EFFECT: enhanced efficiency of colibacteriosis treatment for form animals.

12 tbl, 4 ex

FIELD: chemistry, biochemistry.

SUBSTANCE: invention relates to area of microbiology and biotechnology and can be applied in agriculture. Novel strain Megasphaera elsdenii is characterised by ability to utilise lactate with degree from 40% to 90% even in presence of sugars. Strain with said ability is obtained by method, which includes culturing of sample of paunch liquid. Novel strain Megasphaera elsdenii is applied in method of treatment and prevention of lactic acidosis of ruminants, in composition of veterinary preparation for treatment and prevention of said disease, in method of milk productivity increasing and in method of increasing ruminants fattening efficiency, in method of increasing growth rate and reduction of time of ruminants fattening, in method of reducing morbidity, induced by digestion disorders, and death rate among ruminants from lactic acidosis, as well as in method of increasing efficiency of conversion of ruminants diet based on concentrated forages when transferring ruminant to said diet.

EFFECT: obtaining ability to carry out wide-scale treatment and prevention of lactic acidosis.

17 cl, 3 dwg, 18 tbl

FIELD: medicine.

SUBSTANCE: invention relates medicine area, in particular, gastroenterology, and concerns treatment of GI tract dysbacteriosis. A set containing agents, possessing antagonist action on a GI tract pathogenic microflora and agents for restoration of a normal GI tract microflora (eubiotics and bacteritic preparations), and also independent GI tract electrostimulators are used for this purpose. The method of GI tract dysbacteriosis treatment combines a diet, the specified agents, and also electrostimulator insertion before and-or in the course of treatment.

EFFECT: optimum conditions for effect of eubiotics and bacteritic preparations at the expense of preliminary normalisation of GE tract motor and evacuation functions.

2 cl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I), their optically active stereoisomers, as well as to pharmaceutically acceptable salts possessing properties of ORL1 and -opiate receptors. In general formula , R1 represents H, alkyl(1-6C), []m represents-(CH2)m-, in which m equals 0 or 1, R2 represents halogen, CF3, alkyl(1-6C), phenyl, cyano, cyanoalkyl(1-3C), hydroxy, (1-3C)alkoxy, OCF3, acyl(2-7C), trifluoroacetyl, (1-3C)alkylsulfonyl or trifluoromethylsulfonyl, and n represents integer number 0-4 on condition that when n equals 2, 3 or 4, R2 substituents can be similar or different, A represents saturated ring, []0 and []p represents -(CH2)o and -(CH2)p, and o and p independently correspond to 0, 1 or 2, R3, R4, R5 and R6 independently represent hydrogen, alkyl(1-3C), or (R4 and R6) together can form alkylene bridge, containing 1-3 carbon atoms on condition that when o equals 2, R3 represents hydrogen, and when p equals 2, R5 represents hydrogen, R7 represents H, halogen, alkyl(1-6C). Invention also relates to pharmaceutical composition, intermediate compounds for obtaining formula (1) compounds.

EFFECT: compounds can be used for preparing medication for treating disorders and diseases such as alimentary behaviour disturbances, arterial hypertension.

8 cl, 3 dwg, 1 tbl, 45 ex

FIELD: medicine.

SUBSTANCE: invention concerns experimental medicine and can be used in veterinary science. The Ultrasorb preparation is fed to the animals that are on a vivarium standard diet, within 14 days, based on 3 g/day, admixed with forage. The way prevents development of intestinal dysbacteriosis at animals.

EFFECT: prevention of intestinal dysbacteriosis at animals.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: 24 hours prior to the examination, children aged 3 to 8 year old takes in 100 ml lactulose (Duphalac) with water of room temperature in amount 1-1.5 liters within 4-6 hours. The second dose lactulose (Duphalac) 100 ml follows with water of room temperature in amount 1-1.5 liters. To prevent overaerogenesis and to reduce discomfort, Espumisan (Simethicone) is prescribed in dosage 15 ml 3 times a day. For children aged 8 to 18 years old, there is prescribed 200 ml lactulose (Duphalac) with water of room temperature in amount 1.5-2.0 litres within 4-6 hours followed with the second dose of lactulose (Duphalac) 200 ml with water of room temperature in amount 1-1.5 litres. Additionally Espumisan (Simethicone) is introduced in dosage 15 ml 3 times a day or 3-6 capsules 3 times a day.

EFFECT: effective cleansing of gastrointestinal tract in children of different age, thus ensuring good visualisation of large intestine mucosa and decreasing drug load on organism of younger children, preserving normal microflora of large intestine and preventing overaerogenesis.

2 ex

FIELD: medicine.

SUBSTANCE: there is prescribed gluten-free diet with eliminating cereals and additional order of protein: meat 100.0 g, cottage cheese 100.0 g, or sour cream 100.0 g daily. Creon is dosed 10000 ME at mealtime within 2 weeks. It is combined with physiotherapy exercises (PTE) within 20-30 minutes. During afternoon, every second day circular douche is applied at pressure 1.5-2 atmospheres, water temperature 36-35C for 3-4 minutes within therapeutic course 10-12 procedures. On another days, radon baths are taken at water temperature 36C, dosed 0.75 kBq/l for 8-10 minutes within therapeutic course 8-10 procedures. Electrophoresis is applied daily with 50% Dimexide solution () for small intestine projection by transverse technique, current density 0.05 mA/cm2 within 12-15 minutes within therapeutic course 10-12. The BAPs VC-20, VC-22, E-36, Gi-4 are exposed to red and infrared light daily within 1.5-2 minutes per each point within therapeutic course 10-12 procedures.

EFFECT: reduced specific immunologic markers of autoimmune intestine inflammations and cytokine generation level, normalised immune response of an organism, normalised hormonal and exchange processes.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine and concerns pyelonephritis prevention in experiment. During 10 days preparation "Ultrasorb" is introduced to experimental animals with food in terms of 3 g/day. Then pyelonephritis is modelled by rectal infection with uropathogenic strain of lactose-negative E.Coli at the background of cold stress.

EFFECT: absence or reliable reduction of kidney tissue inflammation in animals which obtained "Ultrasorb".

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatrics and gastroenterology and can be used for treating intestine disbacteriosis in children less than 1 year old. For this purpose bifidumbacterin forte is introduced. First 2-3 days preparation is introduced by 25-30 doses per day in 4 takings. During next 3-4 weeks bifidumbacterin forte is introduced by 5 doses 2 times a day.

EFFECT: method allows increasing efficiency of treatment of disbacteriosis in children less than 1 year old due to application of definite scheme of preparation introduction first in optimally high dose mode, then in supporting doses.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to gastroenterology, and applies to treatment of chronic duodenal obstruction. For this purpose erithromicin is introduced on account of 3.0 mg/kg of body weight 3 times a day. Additionally Alfadol-Ca is introduced in case of initial normocalcemia in dose 1 capsule 1 time a day. In case of initial hypocalcemia Alfadol-Ca dose is 1 capsule 2 times a day. Course of treatment is 3 months.

EFFECT: method ensures elimination of symptoms of chronic duodenal obstruction in patients with functional form of chronic duodenal obstruction in combination with syndrome of disturbed absorption and normalisation of calcium balance in organism.

2 dwg, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns a pharmaceutical industry, in particular to compositions for treatment of adiposity and resistance to insulin at regulation of levels of glucose in blood. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in the blood, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for resistance treatment to insulin at regulation of levels of a glucose and treatment of adiposity at the patient. Way of treatment of adiposity at the people, suffering diabetes, adiposity and resistance to insulin at regulation of levels of a glucose in blood and accepting a medicinal preparation for treatment of diabetes which includes introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures in a combination to an accepted medicinal preparation for regulation of levels of a glucose and treatment of the people, suffering diabetes. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in blood and the hyperglycaemia treatments, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for treatment of adiposity, resistance to insulin and a hyperglycaemia. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and the lipide disturbances, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin and lipide disturbances. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and a hypercholesterinemia, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood, a hypercholesteremia. A way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis. The above described ways of treatment of adiposity, resistance to insulin at regulation of levels of glucose in blood, lipide disturbances, a hypercholesterinemia, an atherosclerosis are effective.

EFFECT: working out of an effective way of treatment of adiposity and resistance to insulin.

16 cl, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns a method of wood processing, in particular to a method of secoisolariciresinol and dihydroquerticin allocation from wood of screen zone of larch or fir. The method of secoisolariciresinol and dihydroquerticin allocation from wood in which the crushed wood from the screen zone of larch (Larix) or fir (Abies) is extracted using an antifloating admixture of an organic dissolvent with water, at the certain content of dissolvent, with reception of the extract containing secoisolariciresinol and dihydroquerticin, an extract is processed for removal of the dissolvent with reception of the final admixture containing secoisolariciresinol and dihydroquerticin. Method of secoisolariciresinol and dihydroquerticin allocation from wood, as it is described above, thus an admixture containing secoisolariciresinol and dihydroquerticin subject to a selective extraction and crystallisation with allocation of secoisolariciresinol and dihydroquerticin. The method of allocation of secoisolariciresinol and dihydroquerticin from wood as it is described above, thus an extract containing secoisolariciresinol and dihydroquerticin, is processed for excision of non-polar components, a supernatant liquid is removed, and the obtained remainder is chromatographed on a silica gel layer with the subsequent excision of column effluent, receiving a dry admixture of secoisolariciresinol and dihydroquerticin.

EFFECT: possibility reception to obtain secoisolariciresinol and dihydroquerticin simultaneously from larch or fir wood in the form of their admixture or separately.

18 cl, 8 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: disclosed medicinal agent contains glucosidase inhibitors of general formula (IIa).

EFFECT: higher clinical effectiveness of mucoviscidosis treatment ensured by repairing the membrane addressing of protein delF508 and its activity as an ionic carrier without cytotoxic effect.

6 cl, 7 dwg, 5 ex

FIELD: pharmacology.

SUBSTANCE: claimed invention relates to field of medications, in particular, to application of Rhodamine 6G in form of 9-(2-etoxycarbonyl)phenyl)-3,6-bis(ethylamino)2,7-dimegylxantyl chloride with chemical formula C28H31N2O3CI as medication for amyloidoses treatment.

EFFECT: describes Rhodamine 6G application with novel purpose.

5 cl, 4 tbl, 17 ex

FIELD: medicine.

SUBSTANCE: invention claims application of naphthalene derivatives: ethylene blue, anthracene, acridine orange, acriflavine, toluidine blue, violamine R, green sulfonic acid, as cancer cell growth inhibitor for treatment of oncology diseases. Application involves administration of medicine up to three times per day by one-time dosage of 0.1 mg to 2 g in the form of solution or inhalation or water solution. Simultaneously medicine is administered rectally or intravenously in the form of 1-5% ointment or suppository. Tumour and metastasis regression is achieved under effect of indicated compounds for osteosarcoma with metastases in lungs, kidney cancer, ovary carcinoma, squamous cell carcinoma, prostate or rectum adenocarcinoma (with metastases to liver), lymphoma, hepatoma, glioblastoma etc. During therapy tumour and metastases disappeared, blood and urine analyses and patient's weight returned to normal. No recurrences have been registered in 4 years.

EFFECT: obtaining medicine inhibiting cancer cell growth for oncology disease treatment.

10 cl, 3 dwg, 17 ex, 6 tbl

FIELD: chemistry, pharmaceutics.

SUBSTANCE: claimed invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts. Compounds of claimed invention possess properties of agonists of mGlu 1 receptors and can find application in treatment of such diseases as psychosis, schizophrenia, Alzheimer's disease, etc. In general formula (I) one of R1 and R2 stands for trifluoromethyl, the other stands for hydrogen; R3, R3' independently on each other stand for hydrogen or halogen.

EFFECT: obtaining medication which possesses properties of agonists of mGlu 1 receptors.

7 cl, 2 tbl, 2 dwg, 17 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the new isoflavon derivative of tectorigenine compound of formula (II) , where R1 represents H, NH2 or SO3M; R2 represents OR'; R3 represents H or -CH2NR"; wherein R' represents H, -CH2COONa or -CH2CH2NMe2; NR" represents or -NMe2; M represents H, Na, K or N+H(CH2CH2OH)3, it also relates to virus inactivating agent having this derivative as an active ingredient and to the method for preparation of the injections on its basis.

EFFECT: developing of production method for the injections on basis of tectorigenine.

20 cl, 10 tbl, 2 dwg,10 ex

FIELD: medicine; pharmacology.

SUBSTANCE: composition is intended for treatment or prevention of insulin resistance of susceptible warm-blooded animals, including humans, and contains selective modulator of estrogen receptor EM-652-HC1, taken in amount determined by therapeutic efficiency.

EFFECT: effective treatment of prevention of insulin resistance development for warm-blooded mammals.

5 cl, 20 ex, 12 tbl, 8 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: invention refers to medicinal agents, specifically to cold preventive composition, containing vitamin C and ginkgetine, and to method of cold prevention provided preventive intake of specified composition.

EFFECT: cold prevention provided preventive intake of specified composition.

16 cl, 4 ex, 9 tbl

FIELD: medicine.

SUBSTANCE: film dosage form sticking to mucous, containing at least on active substance from hemp. The form contains the polymeric matrix, which is used as a reservoir for the active substance and sticking to mucous. The form can have the multilayer structure. It can also contain the non-active ingredients, odorants or aromatisors. The film form is used in treatment of pain in such diseases as carcinomatosis, AIDS, trauma and other disorders.

EFFECT: invention provides better tolerance to administered substances and rapid onset of administered drug, simplifies administration procedures.

19 cl

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to new compounds of coumarone class, namely, to 6-nitro-2-iminocoumarin 3-carboxylic acid 4-toluidide silver salt of the formula (1): that elicits an antibacterial effect and can be used in medicine. Invention provides preparing a new compound eliciting an antibacterial effect with respect to S. aureus, E. coli, and C. albicans with mononuclear cells values 0.25; 0.5 and 7.8 mcg/ml, respectively, and with acute toxicity value LD50 for these compounds 2 460 230 mg/kg.

EFFECT: valuable properties of compound.

1 cl, 1 tbl, 2 ex

Up!